High-Dose ARA-C, Cyclophosphamide and Etoposide with Noncryopreserved Autologous Bone Marrow Transplantation in Acute Myeloid Leukemia in Remission: A Pilot StudyConventional chemotherapy regimens produce 60%–70% complete remissions (CR) in patients with acute myeloid leukemia (AML). Long-term survival...
Jehn U, Heinemann V (1990) Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia. Hamatol Bluttransfus 33:333–338Jehn U, Heinemann V. Intermediate-dose Ara-C/m-AMSA for ...
ClinicalTrials数据库提供临床试验High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)的登记号NCT00136448,试验分期Phase 2以及申办者Dana-Farber Cancer Institute的信息,更过关于临床试验的其他信息查询就在戊戌数据美
From the current studies it can be concluded that comparing the ara-C catabolism to ara-U in leukemic rats and leukemic patients, this process is about 100 times more pronounced in human leukemic cells. The low deaminase activity in leukemic rats probably explains the slow plasma ara-C disappea...
αCD123-ADC, αCD123-targeting antibody-drug conjugate; ANC, absolute neutrophil count; MEC, mitoxantrone, etoposide, and intermediate-dose Ara-C; VAF, variant allele frequency (VAF at initial index detection). Download: Download high-res image (1014KB) Download: Download full-size image Figure...
This might make it possible to lower the therapeutic dose of IMI by co-administering an allosteric binder such as Lu AF60097, preserving the positive effects of tricyclic antidepressants on major depressions while reducing the detrimental side effects such as cardiac arrhythmias and -arrest40 and ...
Interestingly, we found that SA, even in micromolar concentrations, was highly toxic to LECs resulting in a dose-dependent increase in cellular apoptosis as reflected by increasing activity of caspase-3 and annexin V (Figures 5c and d and Supplementary Figure 6A). In contrast, ASCs were highly...
Individuals with lower core fucose might need higher doses of the drug, thus the extent of host IgG core fucosylation may need to be one of the parameters in the calculation of the exact therapeutic dose. Bisecting GlcNAc The addition of bisecting GlcNAc to the IgG glycan by GlcNAc ...
Despite the significant progress in the management of patients with HL, relapsed and refractory disease constitutes a big challenge. According to the current treatment standards, high-dose chemotherapy followed by autoHCT has to be regarded as treatment of choice in the first relapse or primary progr...
It should be deduced that this inconsistency is due to the choice of the values C and/or f. A study for the re-evaluation of C and f is now in progress. For radiation sensitive specimens, MDS271 or a low dose unit (LDU)272 is frequently used to take high resolution ima...